News
HALO
38.46
-1.69%
-0.66
MAHESH KRISHNAN ELECTED TO HALOZYME'S BOARD OF DIRECTORS
Reuters · 20h ago
Press Release: Mahesh Krishnan Elected to Halozyme's Board of Directors
Mahesh Krishnan Elected to Halozyme's Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services. He currently serves as Group Vice President of Growth at DaVita. Halozyme is a leading provider of innovative drug delivery technologies.
Dow Jones · 20h ago
Halozyme (HALO) Receives a Buy from Wells Fargo
TipRanks · 1d ago
Weekly Report: what happened at HALO last week (0415-0419)?
Weekly Report · 4d ago
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
NASDAQ · 04/18 16:45
Laughing Water Capital Q1 2024 Letter
Seeking Alpha · 04/18 16:40
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know
NASDAQ · 04/18 16:00
Halozyme Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Dow Jones · 04/17 15:51
Buy Rating Affirmed for Halozyme on OCREVUS SC Prospects and Enhanze Technology Potential
TipRanks · 04/17 14:55
9 Analysts Have This To Say About Halozyme Therapeutics
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The average price target for the company is $53.78. 9 analysts have provided 12-month price targets for HalozymeTherapeutics. The company has a positive revenue growth rate of 26.75% over the past year.
Benzinga · 04/16 14:01
Halozyme Therapeutics Price Target Maintained With a $50.00/Share by Benchmark
Dow Jones · 04/16 13:37
Benchmark Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target
Benzinga · 04/16 13:27
Analysts Are Bullish on Top Healthcare Stocks: Halozyme (HALO), Cognition Therapeutics (CGTX)
TipRanks · 04/16 11:41
Weekly Report: what happened at HALO last week (0408-0412)?
Weekly Report · 04/15 09:11
Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
Halozyme's ENHANZE technology drives growth, with Q4 2023 revenue up 27% YoY, projecting $915-$985 million in 2024. Key revenue from royalties, notably Darzalex Faspro, with a healthy financial state. Future growth fueled by subcutaneous versions of blockbuster drugs like Opdivo, Ocrevus, and Vyvgart.
Seeking Alpha · 04/10 10:50
S&P 500 Futures Up In Premarket Trading; Halozyme Therapeutics, Revvity Lead
U.S. Stock markets are set to open in two hours. Stocks in Asia were up overnight. Brent crude oil futures were up 0.29%. Bitcoin was down 1.22% to $70,798. The S&P 500 and the Dow were down overnight.
Barron‘s · 04/09 11:31
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Biophytis S.A. Posted a FY23 loss of €0.03 per share. MyMD Pharmaceuticals, Inc. Shares rose 40% in pre-market trading after jumping 22% on Monday. Biophytis shares jumped 55.2% to $0.4920 in today's pre- market trading.
Benzinga · 04/09 10:05
Validea Detailed Fundamental Analysis - HALO
NASDAQ · 04/08 18:04
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Marinus (MRNS) and Halozyme (HALO)
TipRanks · 04/08 10:30
Weekly Report: what happened at HALO last week (0401-0405)?
Weekly Report · 04/08 09:11
More
Webull provides a variety of real-time HALO stock news. You can receive the latest news about Halozyme Thrp through multiple platforms. This information may help you make smarter investment decisions.
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.